You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR TECHNETIUM TC 99M GENERATOR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TECHNETIUM TC 99M GENERATOR

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01437254 ↗ To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer Completed Edmonton PET Centre Phase 1 2011-10-01 The cyclotron production model of Tc-99m pertechnetate (CPERT) has received significant validation in the independent expert review conducted by Natural Resources Canada (NRCan) in the follow up to the Chalk River crisis. The University of Alberta's Edmonton PET Centre and the Edmonton Radiopharmaceutical Centre is a cyclotron / radiopharmacy unit, providing a safe, cost effective, unsubsidized, and reliable supply of radiopharmaceuticals to hospitals and clinics in Edmonton and northern Alberta. A Phase I study is proposed to show safety of CPERT as well as comparability with generator-produced Tc-99m pertechnetate (GPERT) in subjects with well differentiated thyroid carcinoma post-thyroidectomy and prior to planned I-131 Iodide treatment.
NCT01437254 ↗ To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer Completed Natural Resources, Canada Phase 1 2011-10-01 The cyclotron production model of Tc-99m pertechnetate (CPERT) has received significant validation in the independent expert review conducted by Natural Resources Canada (NRCan) in the follow up to the Chalk River crisis. The University of Alberta's Edmonton PET Centre and the Edmonton Radiopharmaceutical Centre is a cyclotron / radiopharmacy unit, providing a safe, cost effective, unsubsidized, and reliable supply of radiopharmaceuticals to hospitals and clinics in Edmonton and northern Alberta. A Phase I study is proposed to show safety of CPERT as well as comparability with generator-produced Tc-99m pertechnetate (GPERT) in subjects with well differentiated thyroid carcinoma post-thyroidectomy and prior to planned I-131 Iodide treatment.
NCT01437254 ↗ To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer Completed AHS Cancer Control Alberta Phase 1 2011-10-01 The cyclotron production model of Tc-99m pertechnetate (CPERT) has received significant validation in the independent expert review conducted by Natural Resources Canada (NRCan) in the follow up to the Chalk River crisis. The University of Alberta's Edmonton PET Centre and the Edmonton Radiopharmaceutical Centre is a cyclotron / radiopharmacy unit, providing a safe, cost effective, unsubsidized, and reliable supply of radiopharmaceuticals to hospitals and clinics in Edmonton and northern Alberta. A Phase I study is proposed to show safety of CPERT as well as comparability with generator-produced Tc-99m pertechnetate (GPERT) in subjects with well differentiated thyroid carcinoma post-thyroidectomy and prior to planned I-131 Iodide treatment.
NCT01930812 ↗ 18F-NaF PET Imaging for Bone Scintigraphy Completed Canadian Institutes of Health Research (CIHR) Phase 3 2014-07-01 The purpose of this study is to compare, in patients with prostate or breast cancer, the accuracy of 18F-NaF PET imaging to 99mTc whole body bone scans with single-photon emission computed tomography (SPECT).
NCT01930812 ↗ 18F-NaF PET Imaging for Bone Scintigraphy Completed British Columbia Cancer Agency Phase 3 2014-07-01 The purpose of this study is to compare, in patients with prostate or breast cancer, the accuracy of 18F-NaF PET imaging to 99mTc whole body bone scans with single-photon emission computed tomography (SPECT).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TECHNETIUM TC 99M GENERATOR

Condition Name

Condition Name for TECHNETIUM TC 99M GENERATOR
Intervention Trials
Cancer of Bone 1
Hyperthyroidism 1
Prostate Cancer Metastatic 1
Thyroid Gland Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TECHNETIUM TC 99M GENERATOR
Intervention Trials
Thyroid Diseases 2
Prostatic Neoplasms 2
Neoplasm Metastasis 2
Bone Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TECHNETIUM TC 99M GENERATOR

Trials by Country

Trials by Country for TECHNETIUM TC 99M GENERATOR
Location Trials
Canada 10
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TECHNETIUM TC 99M GENERATOR

Clinical Trial Phase

Clinical Trial Phase for TECHNETIUM TC 99M GENERATOR
Clinical Trial Phase Trials
Phase 3 3
Phase 1/Phase 2 1
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TECHNETIUM TC 99M GENERATOR
Clinical Trial Phase Trials
Completed 3
Recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TECHNETIUM TC 99M GENERATOR

Sponsor Name

Sponsor Name for TECHNETIUM TC 99M GENERATOR
Sponsor Trials
Natural Resources, Canada 2
Canadian Institutes of Health Research (CIHR) 2
British Columbia Cancer Agency 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TECHNETIUM TC 99M GENERATOR
Sponsor Trials
Other 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.